Cargando…

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function

Introduction: Allogeneic stem cell transplantation (ASCT) is a crucial therapeutic strategy for hematological and non-hematological disorders. Poor graft function (PGF) after ASCT presents a critical challenge that does not have a standardized treatment approach. A thrombopoietin-mimetic oral drug e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arslan Davulcu, Eren, Akad Soyer, Nur, Vural, Filiz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544786/ https://www.ncbi.nlm.nih.gov/pubmed/37790070 http://dx.doi.org/10.7759/cureus.44555

Ejemplares similares

Use of Eltrombopag in Improving Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation
por: Master, Samip, et al.
Publicado: (2018)

Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag
por: Tang, Cen, et al.
Publicado: (2018)

Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant: SARS-CoV-2 Vaccine as a Potential Trigger
por: Azem, Amin, et al.
Publicado: (2022)

Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
por: Chiesa, Robert, et al.
Publicado: (2022)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
por: Noviello, Maddalena, et al.
Publicado: (2023)

Prognostic Value of Hematogones in Patients With Hematopoietic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
por: Mori, Hirotaka, et al.
Publicado: (2023)

Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation
por: Ren, Xiying, et al.
Publicado: (2021)

Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children
por: Masetti, Riccardo, et al.
Publicado: (2023)

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation
por: Martin, Paul J., et al.
Publicado: (2022)

Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation
por: Miyata, Masahiro, et al.
Publicado: (2023)

Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic
por: Devine, Steven M., et al.
Publicado: (2023)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
por: Lakkaraja, Madhavi, et al.
Publicado: (2022)

Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades
por: Nishiwaki, Satoshi, et al.
Publicado: (2022)

Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant
por: Pérez-Valencia, Amanda Isabel, et al.
Publicado: (2022)

Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation
por: Kanaan, Sami B., et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
por: Murthy, Hemant S., et al.
Publicado: (2023)

Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure
por: Sabulski, Anthony, et al.
Publicado: (2021)

EASIX-1year and late mortality after allogeneic stem cell transplantation
por: Kordelas, Lambros, et al.
Publicado: (2023)

Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft-versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution Experience
por: Hashmi, Hamza, et al.
Publicado: (2020)

An Unusual Presentation of Nocardiosis in an Allogeneic Transplant Recipient
por: Ibrahim, Uroosa, et al.
Publicado: (2016)

Treatment of allosensitized patients receiving allogeneic transplantation
por: Ciurea, Stefan O., et al.
Publicado: (2021)

Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant
por: Rubinstein, Jeremy D., et al.
Publicado: (2022)

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities
por: Hassanein, Mona, et al.
Publicado: (2021)

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
por: Jentzsch, Madlen, et al.
Publicado: (2022)

Selected memory T cells infused post–haploidentical hematopoietic stem cell transplantation persist and hyperexpand
por: van Beek, Jasper J. P., et al.
Publicado: (2022)

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
por: Gooptu, Mahasweta, et al.
Publicado: (2022)

Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
por: Weber, Daniela, et al.
Publicado: (2022)

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
por: Tamari, Roni, et al.
Publicado: (2023)

Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation
por: Yilmaz, Asu Fergun, et al.
Publicado: (2017)

Circulating microbial cell–free DNA is increased during neutropenia after hematopoietic stem cell transplantation
por: Blair, Lily M., et al.
Publicado: (2023)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

Type 1 interferon to prevent leukemia relapse after allogeneic transplantation
por: Magenau, John M., et al.
Publicado: (2021)

Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation
por: Petersdorf, Effie W., et al.
Publicado: (2023)

Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning
por: Townsend, William M, et al.
Publicado: (2013)

Adult Onset Langerhans Cell Histiocytosis: Clinical Characteristics and Treatment Outcomes
por: Arslan Davulcu, Eren, et al.
Publicado: (2023)

PB2468: A RETROSPECTIVE STUDY OF ELTROMBOPAG IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: MA, Liangming, et al.
Publicado: (2023)

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience
por: Maurer, Katie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vl3puebrq7nujc2mc9bmtc22bl